CSIMarket
 
Panbela Therapeutics Inc   (PBLA)
Other Ticker:  
 
 
Price: $0.3500 $-0.01 -2.098%
Day's High: $0.35 Week Perf: 2.94 %
Day's Low: $ 0.35 30 Day Perf: -14.43 %
Volume (M): 0 52 Wk High: $ 1.50
Volume (M$): $ 0 52 Wk Avg: $0.46
Open: $0.35 52 Wk Low: $0.30



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 5
 Employees 26
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Panbela Therapeutics Inc
Panbela Therapeutics Inc. is a clinical-stage biotechnology company that specializes in the development of targeted therapeutics for the treatment of various cancers. The company focuses on utilizing its proprietary platform technology, known as the Panbela Platform, which combines multiple drugs into a single, potent therapeutic agent.

Through its unique platform, Panbela Therapeutics aims to enhance the effectiveness of cancer treatments while minimizing the side effects typically associated with chemotherapy and other conventional treatments. The company's drug candidates are designed to target specific cancer cells, ensuring precise and efficient treatment.

Panbela Therapeutics conducts extensive research and development to identify and develop innovative therapies for different types of cancers. The company is committed to improving patient outcomes and achieving significant advancements in cancer treatments.

Overall, Panbela Therapeutics Inc. is a biotechnology company at the forefront of developing transformative therapies to combat cancer, offering new hope and potential solutions for patients worldwide.


   Company Address: 712 Vista Blvd #305 Waconia 55387 MN
   Company Phone Number: 479-1196   Stock Exchange / Ticker: PBLA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.59%    
LLY        7.39% 
PFE   -2.64%    
REGN        4.92% 
TEVA   -3.53%    
VTRS   -3.15%    
• View Complete Report
   



Announcement

Panbela Pioneers First Patient Enrolled in STK11 Mutant NSCLC Phase I Trial at Moffitt Cancer Center,

Published Tue, Sep 24 2024 12:01 PM UTC

In a significant stride towards addressing an urgent unmet medical need, Panbela Therapeutics, Inc. (OTCQB: PBLA) has announced the enrollment of the first patient in its Phase I dose escalation study aimed at treating STK11 mutant non-small cell lung cancer (NSCLC). The study is being conducted at the renowned Moffitt Cancer Center, a hub for leading oncological research. D...

Announcement

Promising Safety Profile of Ivospemin in Combination Therapy for Metastatic Pancreatic Ductal Adenocarcinoma Demonstr...

Published Mon, Jun 24 2024 12:00 PM UTC

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapeutics for patients with urgent unmet medical needs, recently announced the favorable outcome of the third independent safety review of their ongoing Phase 3 ASPIRE clinical trial. This trial aims to evaluate the efficacy and safety of ivospemin in combination ...

Announcement

Panbelas Eflornithine Shows Promise in Treating Gastric Premalignant Conditions: Impact and Future Prospects

Published Mon, Jun 10 2024 12:00 PM UTC

Panbela Therapeutics, a clinical stage biopharmaceutical company, has made significant strides in developing disruptive therapeutics for patients with urgent unmet medical needs. Their latest achievement involves the evaluation of the safety and efficacy of Eflornithine (Difluoromethylornithine, DFMO) in patients with gastric premalignant conditions in high incidence areas o...

Panbela Therapeutics Inc

Panbela Therapeutics Inc Reports Growth and Achievements in Cancer Treatment Innovation, Despite Decrease in Financial Results for Q1 2024

Panbela Therapeutics Inc, a clinical stage company specializing in disruptive therapeutics for urgent unmet medical needs, recently provided a business update and reported its financial results for the quarter and full year ending December 31, 2023. The company also announced significant advancements and achievements in the field of cancer treatment.
One of the notable developments for Panbela Therapeutics is the issuance of a new patent in the United States and Canada for a fixed dose combination of Eflornithine and Sulindac. This combination therapy, developed in collaboration with leading pharmaceutical company Sanofi, represents a significant step forward in the fight against cancer. The new patent underscores Panbela's commitment to developing innovative treatments for cancer patients and further solidifies the company's reputation as a key player in the industry.

Announcement

Panbela Therapeutics Advances Cancer Treatment with New Patent and Exciting Clinical Trial Results

Published Mon, May 6 2024 12:01 PM UTC

Panbela Therapeutics, Inc. (OTCQB: PBLA), a renowned clinical stage biopharmaceutical company, is making significant strides in the field of cancer treatment. The company recently announced the issuance of a new patent in the United States and Canada for a fixed dose combination of Eflornithine and Sulindac. This innovative combination therapy has been developed in collabora...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com